SuliXen: Final Phase I data

Final data from a cross-over, Russian Phase I trial in 12 healthy volunteers showed that 0.1 and 0.3 IU/kg subcutaneous SuliXen was more potent than 0.2 IU/kg Lantus insulin glargine. SuliXen also ha...